argenx and Broteio Pharma jointly develop antibodies for severe autoimmune diseases

Share this article

argenx announces its new collaboration with Broteio Pharma. Broteio will perform preclinical research using argenx' SIMPLE antibody platform after which argenx has the exclusive option to license the program for clinical development.

argenx announced today that it has entered into a new collaboration with Dutch biotech Broteio Pharma to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation.

Read more about argenx

“This collaboration represents the latest success for our Innovative Access Program and aligns with our corporate mission to develop differentiated antibodies for cancer and severe autoimmune diseases. The novel antibody targets a component of the complement cascade with therapeutic potential in both orphan and large market indications like Ischemia/Reperfusion Injuries (IRI),” comments Tim Van Hauwermeiren, CEO of argenx. “This new therapeutic antibody has the potential to act alongside our lead product candidate ARGX-113 in a synergistic fashion. ARGX-113 targets FcRn in order to clear pathogenic IgG antibodies while our new complement-targeted antibody can also address IgM mediated autoimmune diseases. This transaction positions us to further build out the depth and breadth of our autoimmune disease pipeline.”

Under the terms of the agreement, argenx and Broteio will jointly develop the complement-targeted antibody to establish preclinical proof-of-concept using argenx’s proprietary suite of technologies. Upon successful completion of these studies, argenx may exercise an exclusive option to license the program and assume responsibility for further development and commercialization.

Through its Innovative Access Program (IAP) argenx is able to serially collaborate closely with academic experts and small biotech companies, bringing antibody discovery technologies to the heart of novel target research. The IAP allows argenx’ partners use of its technologies for the development of antibodies to help validate novel targets. In return, argenx is granted early access to these targets. The diversity of argenx’s SIMPLE AntibodyTM immune repertoires help streamline target validation, with the potential to transform novel proteins into next generation therapeutic antibody programs.